Variety of qualified individuals: CDEC mentioned the uncertainty in the number of patients with reasonably critical to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are categorized as getting mild or reasonable condition might have a severe bleeding phenotype, https://paulo873kov8.wikirecognition.com/user